The new drug muvalaplin may be the world’s first drug to treat previously untreatable “bad cholesterol,” according to a new Australian study.
The study, published on Aug. 28 in the Journal of the American Medical Association (JAMA), showed that muvalaplin reduced lipoprotein(a), or Lp(a), a genetically inherited carrier for “bad cholesterol,” by up to 65 percent after two weeks of daily treatment.
